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ABSTRACT 57 
The complexity of the clinical management of neuroendocrine neoplasia (NEN), is exacerbated 58 
by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in 59 
currently available imaging reflect difficulties in measuring an intrinsically indolent disease, 60 
resolution inadequacies, inter-/intra-facility device variability, and that RECIST (Response 61 
Evaluation Criteria in Solid Tumours) criteria are not optimal for NEN. Limitations of currently 62 
utilized biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-63 
specific enolase, pancreastatin), monoanalyte measurements, and lack sensitivity, specificity 64 
and predictive capacity. None meet NIH metrics for clinical usage. A multinational, 65 
multidisciplinary Delphi consensus meeting of NEN experts (n=33) assessed current imaging 66 
strategies as well as biomarkers in NEN management. Consensus (>75%) was achieved for 67 
78% of 142 questions. The panel concluded that morphological imaging has diagnostic value. 68 
However, both imaging and current single-analyte biomarkers exhibit substantial limitations in 69 
measuring disease status and predicting therapeutic efficacy. RECIST remains sub-optimal as a 70 
metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced 71 
information regarding precise disease status and treatment response. The group concluded that 72 
circulating mRNA was a more effective tool than current monoanalyte NEN biomarkers and 73 
clinical data were auspicious. It resolved that circulating multianalyte mRNA (NETest) had 74 
clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it 75 
was concluded that a combination of tumour spatial and functional imaging with circulating 76 
transcripts (mRNA) would represent the future strategy for real-time monitoring of disease 77 
progress and therapeutic efficacy. 78 
 79 
  80 
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INTRODUCTION 81 
The management of neuroendocrine neoplasms (NENs, also called “NETs”) remains clinically 82 
challenging despite advances in classification systems [1], inauguration of novel therapies, 83 
innovations in imaging and the introduction of multidisciplinary management strategies [2]. In 84 
particular, the management of NEN reflects diverse approaches often based upon empiric 85 
pronouncements, local practical experience or the availability of certain therapies. Despite the 86 
promulgation of effective and applicable guidelines (e.g., WHO/ENETs classification of 2010) [3, 87 
4] and their regular reassessment, a critical limitation is the dearth of large, randomized 88 
prospective trials. The precise delineation of definable strategies is further constrained by the 89 
tumour heterogeneity (diverse cell types, disparate molecular regulatory mechanisms and ill-90 
understood oncogenic drivers) [5, 6]. As a consequence, five-year survival rates diverge widely 91 
(15-95%), depending on the primary site, variable tumour biology, disease extent at diagnosis, 92 
available therapeutic options and designated centers of care [7-9]. Therapeutic options remain 93 
diverse and run the full gamut from mechanistic excision to pharmacological intervention and 94 
the infusion of radioactive somatostatin analogs [10]. Strategies include somatostatin receptor 95 
agonists, “targeted” agents (mTOR inhibitors, VEGF antagonists), immunotherapy (interferon), 96 
cytotoxic chemotherapy, peptide receptor radionuclide therapy (PRRT), external radiation, and 97 
interventional radiological or probe-directed ablation [11]. In those with “indolent tumour 98 
behavior”, a watch-and-wait-strategy is considered appropriate in certain selected cases [12]. 99 
Apart from “early identified” (usually serendipitous) appendiceal, rectal or gastric NETs, cure is 100 
uncommon and overwhelmingly, the majority of treatment includes diverse combinations of 101 
strategies to delay local or metastatic disease progression [13]. Given their relatively slow 102 
growth, continual assessment by imaging, biomarker levels and overall survival represents the 103 
fundamental basis for all management strategies. The need to monitor tumour responsiveness, 104 
both in clinical trials and in routine practice, is mandatory given the range of expensive, 105 
empirical and often times toxic treatment choices utilized [14].  106 
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For many non-neuroendocrine neoplasms, therapeutic responsiveness is assessed 107 
through imaging, but for NENs, this has well-described limitations [15-17]. Anatomic imaging 108 
using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria exhibits well-109 
documented limitations [18-20]. These include issues with lesion dimensionality and 110 
measurements thereof, effects of therapy on lesion appearance itself, difficulties with 111 
reproducibility and accurate delineation of metastatic disease, particularly extra-liver disease. 112 
The development of new lesions is probably the most powerful indicator of disease progression. 113 
Functional imaging with somatostatin receptor-based strategies e.g., 68Ga-SSA-PET/CT, has 114 
proved of considerable value [21], but limited spatial resolution (6-8 mms for PET-scanners) and 115 
partial volume effects, constrain the ability to delineate small lesions. As a consequence, timely, 116 
clinically reproducible assessments of progression remains unattainable [22, 23]. Changes in 117 
the 68Ga-SSA tumour standardized uptake value (SUV) during treatment have not been a 118 
reliable measure for therapy monitoring [24, 25]. 18FDG-PET, though useful prognostically, is 119 
not established as an early harbinger of tumour progression [26]. Despite significant advances, 120 
current imaging strategies in NENs remain sub-optimal [27, 28] and exhibit significant 121 
limitations. In particular, the identification and delineation of residual (and occult) disease is 122 
difficult.  123 
Credible general biomarkers with broad clinical utility for gastroenteropancreatic (GEP)-124 
NENs remain unavailable although chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic 125 
acid (5-HIAA; in serotonin-secreting tumours) have been used in this capacity [29]. Secretory 126 
(monoanalyte) biomarkers for specific tumour types (insulinoma: insulin, gastrinoma: gastrin, 127 
glucagonoma: glucagon, VIPoma: VIP), are effective serum indicators of tumour activity, but 128 
since this group of lesions represent a minority of NENs (<3-5%), their broad utility is limited. 129 
CgA is a constitutive product of the neuroendocrine cell secretory granule and is measurable in 130 
serum or plasma. It has been variously reported to correlate with tumour biology and mass and 131 
prognosticate survival [30, 31]. Despite initial enthusiasm, the limitations of CgA have become 132 
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increasingly evident. There is considerable discrepancy as to whether alterations in CgA have 133 
clinical utility in the identification of progressive disease. Although there has been some 134 
improvement regarding comparable unit use, there is no reference CgA standard and wide 135 
variations exist in the assay measurements in different laboratories [30]. Furthermore, the 136 
sensitivity of CgA ranges from 60–90% with a specificity <50% (depending on the population 137 
studied) [32]. This reflects the CgA elevations associated with numerous non NEN-related 138 
conditions including renal failure, cardiac disease, other neoplasia as well as PPI administration 139 
[30].  140 
The complexity and diversity of the biological behavior of a cancer or its response to 141 
therapy have been effectively addressed in scientific publications [33, 34]. The limitations of 142 
secretory products to define the permutations of oncogenic genomic regulators are apparent, 143 
and have led to the development of molecular technologies to better delineate cancer biology 144 
[35, 36]. This biological research has identified extensive interfacing mechanisms that delineate 145 
GEP-NEN neoplastic development [37]. A key unmet need is the identification of what 146 
constitutes the driver of neoplastic development (i.e., driver mutations) and whether this is 147 
clinically actionable i.e., targetable, and can be used as a predictive biomarker.  148 
The majority of tumors (~95%) do not exhibit germline mutations [6, 38]. While genomic 149 
studies have revealed a number of sporadic genomic alterations, particularly in pancreatic 150 
NENs, the relationship between specific genes and tumour pathobiology remains unclear [5]. 151 
Unlike the majority of cancers, activating mutations are infrequent if not largely unknown in 152 
GEP-NEN [5] with most tumours exhibiting mutations (when identified) in tumour suppressor 153 
genes. While genomic studies seeking underlying driver mutations have proven disappointing 154 
[39, 40], transcriptome assessments have been useful in identifying and differentiating the 155 
different subtypes of NENs (based on origin e.g., pancreatic versus small intestinal, and 156 
aggressiveness e.g., non-progressive versus malignant/metastatic) [41, 42] and have 157 
demonstrable predictive utility at a tissue level [43]. More recently, blood-based assays (CTCs, 158 
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miRNA and circulating mRNA) have been developed. The most extensively investigated 159 
biomarker tool is blood-based multianalyte transcript analysis [44-54]. Blood gene expression of 160 
tumour biomarkers closely correlates with tumour tissue expression levels, and analysis of 161 
relevant clusters captures NEN biology facilitating accurate definition of clinical status [37]. The 162 
clinical application of such blood-based information to the management of NEN disease has 163 
therefore become a subject for investigation. Likewise, the concept of fusing such data with 164 
functional imaging to provide a synergistic monitoring platform is worthy of consideration, 165 
especially given the current limitations in accurate monitoring. 166 
Although biomarkers have been used in conjunction with imaging as adjuncts to inform 167 
clinical decision making, “biochemical” responses using monoanalytes are often non-concordant 168 
with image-based assessments [10, 55]. The detailed analysis of other neoplastic diseases has 169 
led to the recognition that evaluation of monoanalyte secretory products (exocytotic or secreted 170 
proteins) alone fails to adequately describe the diversity of neoplastic pathobiology [56]. Thus, 171 
complex analytic strategies measuring diverse regulators of neoplastic cell biology interfaced 172 
with mathematical algorithms to facilitate interpretation have been developed for breast, lung 173 
and hematological malignancies [57-60]. A key unmet need therefore remains the development 174 
of a clinically applicable, multianalyte biomarker that captures NEN behavior and can be used to 175 
guide clinical management strategies. The use of such blood-based molecular information in 176 
combination with functional imaging would provide non-invasive real time multidimensional 177 
information in regard to tumour behavior. 178 
Based upon the need for a better understanding of the relationship between imaging and 179 
therapeutic assessment in NEN disease and the emergence of molecular-based biomarkers 180 
that have utility in assessing disease status e.g., blood-based multianalyte transcript analysis 181 
NETest [37], a meeting of multidisciplinary experts in the field was convened in Casteldefells, 182 
Spain in March 2015. The goals of this forum were twofold. Firstly, to establish a consensus on 183 
the state of the art of imaging and biomarkers in NEN and secondly, to identify how these two 184 
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information disciplines could be interfaced to provide added value in clinical decision-making 185 
and therapeutic response assessment. This meeting represents a follow-up of a previous, more 186 
biomarker focused Delphi consensus meeting that specifically examined the current status of 187 
circulating analytes in the management of GEP-NETs in respect of their individual metrics and 188 
clinical utility [61]. 189 
 190 
MATERIALS AND METHODS 191 
Thirty-three multinational experts in the field of NEN disease diagnosis and management were 192 
identified including nuclear medicine physicians (n=12; A. Kjaer, E. Krenning, D. Kwekkeboom, 193 
L. Bodei, V. Ambrosini, R. Baum, J. Cwikla, G. Paganelli, S. Severi, H. Maecke, V. Prasad, I. 194 
Virgolini), radiologists (n=2: A. Sundin, K. Koopmans), endocrinologists (n=2; M. Pavel, A. 195 
Grossman), gastroenterologists (n=1, R. Jensen), oncologists (n=9, K. Oberg, M. Tesselaar, M. 196 
Kulke, N. Fazio, R. Salazar, J. Strosberg, A. Walenkamp, M. Cives, T. Meyer [see Authors 197 
contributions]), pathologists (n=1, A. Scarpa), basic scientists (n=3, M. Kidd, I. Drozdov, T. 198 
Korse) and surgeons (n=3: M. Falconi, A. Frilling, I. Modlin). The Delphi method [62] was 199 
utilized to achieve consensus on 142 questions, using a 75% agreement level as the basis for 200 
achieving consensus [61]. Questions were categorized into four major groups (Therapeutic 201 
Management, Imaging, Molecular Status of NETs, and Biomarkers). The first iteration of the 202 
statements to be discussed was developed by a core group (KO, EK, LB, IMM) and distributed 203 
to all participants eight weeks prior to the conference. This first round electronic assessment 204 
was undertaken to eliminate or redefine inconsistencies or ambiguous statements [61]. After 205 
integration of the primary assessment comments from all participants, this second list (revised) 206 
of statements/questions (yes or no responses) was electronically distributed one month ahead 207 
of the consensus meeting. All participants provided answers to this interrogatory. The collated 208 
results of the entire group responses were made available to all participants at the initiation of 209 
the meeting. The meeting format comprised two co-moderators for each discussion session. 210 
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Any question with less than 75% prior agreement (either Consensus: Yes or Consensus: No) 211 
was then reviewed and discussed by the entire panel and re-voted on. Voting was anonymous 212 
(electronic touch pad) with re-wording of ambiguous, controversial or non-consensus 213 
statements as proposed by participants with the objective of attaining  a 75% agreement 214 
threshold [61]. Up to five re-iterations of a proposal were undertaken before considering an 215 
issue resolved. Resolution was achieved in 78%. Not all questions (22%) resulted in a 216 
consensus.  217 
 218 
RESULTS 219 
A total of 142 questions and sub-questions were posed. First round electronic consensus was 220 
achieved prior to the March 2015 meeting in 69 (48.5%). At the meeting, after 221 
statement/question reformulation and repeat voting, final consensus was achieved on 111 222 
(78%). The full lists of statements and voting results are documented in the Appendix. Three 223 
participants (ID, HM, DK) were unable to attend the meeting and participate in the final round of 224 
voting. The final consensus therefore includes input from these members at rounds 1 and 2 but 225 
not round 3. 226 
 227 
A. Therapeutic Management 228 
Consensus was achieved on 30 questions (47%) prior to the meeting. A further 16 (total of 72%) 229 
met consensus after discussion and re-voting. The panelists agreed that optimal management 230 
strategies required assessment of information based upon: histology, grade and stage, specific 231 
and non-specific symptoms, as well as knowledge regarding the patient’s overall condition. 232 
However, they also decided that clinical knowledge alone was inadequate for predicting whether 233 
a NEN would be progressive or exhibit stable disease. Although a wait-and-see strategy was 234 
considered an acceptable management strategy, there was full concurrence that current 235 
diagnostic parameters were neither of adequate sensitivity nor specificity for defining progress. 236 
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Moreover, currently available Randomized Controlled Trial (RCT) data were considered 237 
insufficient to accurately delineate the optimal therapeutic sequence strategy in NEN disease. 238 
Overall, the group concluded that there was a paucity of rigorous data available to facilitate 239 
objective, clinical decision-making. 240 
In respect of imaging, current standard diagnostic parameters are neither sensitive nor 241 
specific enough to define progress. Additional predictors of the individual course of disease are 242 
therefore required to identify individuals in whom early treatment may be of benefit. This would 243 
include additional imaging parameters. Limitations in the assessment of therapeutic responses 244 
with current imaging has a negative impact on patient management. Limitations in the 245 
discriminant index of both anatomic and functional imaging diminished the accuracy of 246 
assessment of therapeutic response. Somatostatin receptor (SSR) density was considered a 247 
relevant parameter but knowing the liver tumour load and pretreatment growth rate were 248 
considered important predictors of disease course. It was agreed that additional predictors of 249 
the individual course of a specific tumour are required to define those in whom early treatment 250 
may be of benefit. Biomarkers including but not limited to tissue gene signatures, circulating 251 
genetic information and mutational events were considered critical requirements for such a 252 
strategy. 253 
The thresholds and cut-offs for defining histopathology, Ki67 were considered 254 
problematic for defining when chemotherapy should be considered. No consensus could be 255 
reached upon the precise applicable cut-off. Ki67 was not considered a relevant parameter for 256 
predicting SSA response. Surgery was considered the only curative treatment and a blood 257 
signature that could predict disease relapse following R0/R1 (primary or liver) resection was 258 
agreed upon as an important requirement. It was identified that selective internal radiation 259 
therapy (SIRT), radio frequency ablation (RFA) and trans-arterial (chemo-) embolization 260 
(TACE/TAE) were all effective in metastatic liver disease, though individual modalities differed in 261 
efficacy based upon patient selection and disease status [63]. Individual interventions were 262 
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noted to have adverse events though lack of comparable data prevented rigorous comparison 263 
[63]. No consensus was reached regarding associations with adverse events. Regarding, 264 
somatostatin analogs (SSAs), use should not only be limited to midgut and pancreatic NENs 265 
with K-i67<10%, but no consensus could be reached as to whether SSAs were effective early in 266 
the disease course to prevent disease progression. Likewise, it was not accepted that there was 267 
evidence that above-label doses should be used in non-functioning progressive disease. There 268 
also was not sufficient data to support the use of SSAs as anti-proliferative agents in patients 269 
with significant metastatic burden e.g., >50% neuroendocrine tumour liver metastases (NELM) 270 
and/or extra-hepatic metastases. The panel was unsure whether Everolimus had a role in non-271 
pancreatic NEN disease (it should be noted that this meeting occurred prior to the publication of 272 
the Radiant-4 study [64]). Controversy was also apparent regarding initial therapeutic use of 273 
chemotherapy. The group was of the opinion that PRRT might warrant consideration at an 274 
earlier time-point in the therapeutic strategy for management of NETs (it should be noted that 275 
this meeting occurred prior to the availability of the NETTER-1 study results [65]). It was, 276 
however, deemed appropriate to consider the use of PRRT before other targeted therapies. 277 
Overall, a substantial lack of consensus (~28%) was evident for GEP-NEN therapeutic 278 
management. This likely reflects the individualized, empiric-based approaches and the 279 
divergent views of European and US experts. 280 
 281 
B. Imaging 282 
Consensus was achieved in 72% of questions (Figure 1). There was agreement that CT or MRI 283 
should be used in conjunction with functional imaging. 68Ga-SSA-PET/CT was preferred to 111In-284 
pentetreotide scintigraphy for functional imaging. 68Ga-SSA-PET/CT was considered the 285 
preferred approach compared to 18F-DOPA imaging for pancreatic and small intestinal NEN 286 
diagnosis. 18F-FDG-PET/CT was considered useful for differentiating high from low grade 287 
tumours which might have future implications for staging. The technique, however, has 288 
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prognostic implications although this requires validation in larger series. No consensus, 289 
however, was reached regarding combining 18F-FDG- and 68Ga-SSA-PET/CT or the timing of 290 
imaging for use of each of these modalities in a diagnostic setting. 291 
Imaging was considered the best current modality for measuring treatment efficacy but 292 
no consensus was achieved regarding the optimal strategy, PET/CT or CT or MRI. It was 293 
agreed that RECIST criteria were not appropriate for defining therapeutic responses in NETs at 294 
least for biological therapy, and furthermore inclusion of morphologic parameters e.g., 295 
attenuation measurements, were not considered useful. No consensus was reached regarding 296 
whether “cold” analogs e.g., Sandostatin or Lanreotide (non-radioactive without bound 297 
isotopes), should be discontinued before somatostatin receptor imaging (SRI). Overall, the 298 
heterogeneity in SSR expression was considered a potential sensitivity limitation to this 299 
approach since current ligands are SSR2/5 avid. Similarly, the SUVmax was also not considered 300 
an entirely reliable parameter for assessing patient management based on current ligand-301 
receptor affinities [66]. Based upon currently available studies, different 68Ga-DOTA-SSA 302 
peptides (DOTA-TOC, DOTA-NOC and DOTA-TATE) were individually as effective in their 303 
diagnostic accuracy. All were considered to have clinical utility in determining clinical 304 
management. 305 
Overall, imaging was considered more sensitive than existing biomarkers for detecting 306 
disease. The group concurred that more effective circulating biomarkers would be a useful 307 
adjunct for assessing treatment. It was agreed that current biomarkers such as CgA do not 308 
correlate with imaging, particularly 68Ga-DOTA-SSA and 18F-FDG imaging. No consensus could 309 
be reached for the relationship between CT or MRI and CgA. Overall, the panel agreed that 310 
integration of a clinically relevant, biologically effective biomarker strategy into response criteria 311 
was required to improve NEN therapy monitoring. 312 
 313 
C: Molecular Status of NETs 314 
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Consensus was achieved in the majority of questions (95%). Metabolic pathways were agreed 315 
to be poorly characterized. The PI3K/mTOR pathway was not considered to be the principal 316 
growth regulatory pathway in NENs. It is as yet unclear what constitutes the precise mechanistic 317 
basis of the critical growth regulatory pathways of neuroendocrine tumour cells. Despite the 318 
proposal of numerous putative targetable pathways, current agents are not generally accepted 319 
as being of robust clinical utility [67]. Alternative pathways remain to be defined. Mutations in the 320 
mTOR pathway were noted to occur in <15% of pancreatic NENs, and the objective response 321 
rate for Everolimus (mTOR pathway inhibitor) is ~10% with disease stabilization in ~75% [68]. 322 
The discrepancy between mutation rate and therapeutic efficacy is currently difficult to reconcile. 323 
Selective PI3K inhibitors were considered useful for overcoming Everolimus resistance although 324 
the mechanisms of resistance remain to be defined. Mutations in the ATRX/DAXX pathways 325 
were not considered major indicators of clinical outcome and it was agreed they should not be 326 
routinely assessed in pancreatic NENs. In patients with multiple endocrine neoplasia type I 327 
(MEN1) syndrome (germline MEN-1 mutation), the type of menin mutation was not considered 328 
to be of prognostic significance. Alterations in methylation patterns were likewise not considered 329 
clinically useful, while O6-methylguanine DNA transferase deficiency was regarded as not 330 
significant in influencing the choice of therapy. Irrespective of the individual molecular 331 
abnormality described, cell line models were considered unreliable for identifying and confirming 332 
the utility of any targeted agent.  333 
No consensus could be reached regarding the role of VEGF expression and tumour 334 
aggressiveness. It was agreed that immunohistochemistry for SSR was not needed to define a 335 
treatment strategy but immunohistochemistry (IHC) e.g., CDX2 and PAX6 was recommended 336 
when a primary site was unknown (CUP). Gene profiling, in this setting (CUP) was, however, 337 
not clinically recommended. Overall, it remained unclear how molecular alterations, particularly 338 
at a DNA level, could potentially improve clinical management strategies. It was concluded that 339 
molecular alterations as currently defined did not have a current role in NEN treatment, but the 340 
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panel did support continued investigation in these areas to further define the molecular basis of 341 
NEN disease. 342 
 343 
D. Biomarkers 344 
A consensus was reached in 89% of questions (Figure 2). It was agreed that despite the 345 
paucity of DNA-related clinically actionable biomarkers, genomics technology had significant 346 
potential for identifying novel tissue biomarkers. The conclusion, however, was that at present 347 
insufficient specific mutations and treatment-targetable mutations had been identified. As such, 348 
circulating DNA was therefore not considered a viable option for the development of a 349 
biomarker.  350 
In general, circulating tumour cells (CTCs) were agreed not to be reliable, sensitive or 351 
specific for the detection (88% No) and diagnosis (92% No) of NENs. Furthermore, once 352 
tumours were diagnosed, CTCs were considered not to correlate with grade (77% No) or to 353 
have clinical utility as either a prognostic (85% No) or predictive biomarker (77% No). No 354 
consensus was achieved relating the utility of CTCs as an indicator of tumour burden. While 355 
miRNA was considered interesting and potentially useful as a circulating biomarker, the group 356 
agreed that current technology was not adequately robust to support clinical usage. 357 
Metabolomics was also considered of positive interest (83% Yes) as was the identification of 358 
novel blood GEP-NEN biomarkers. The consideration of metabolomic assessment in urine was 359 
not supported (83% No). Tumour transcriptomes and mRNA studies were agreed to be useful 360 
for identifying tissue biomarkers and more sensitive than standard biomarkers. Circulating 361 
mRNA assays were agreed to be worthy of further investigation given their potential clinical 362 
utility.  363 
 364 
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DISCUSSION 365 
The Delphi method, originally developed by the RAND Corporation [62], has been used 366 
extensively to develop consensus in healthcare. We have previously assessed its utility in 367 
similar clinical decision-making settings [61, 69]. In this meeting, a substantial overall consensus 368 
(~80%) was achieved with 31 questions (~20%) ultimately unresolved (no consensus achieved). 369 
A consensus level of 75% was used as clear evidence of a majority opinion. Voting was 370 
anonymized (electronic) and followed by discussion when there was no consensus. The actual 371 
numbers of participants who completed all three rounds (n=30, 91% inclusion) is similar to other 372 
Delphi-based studies for NENs and met the acceptability criteria for validity [69, 70]. 373 
Therapeutic management and imaging achieved the lowest consensus (72%) compared 374 
to molecular biology and biomarkers (88-95%). This likely reflects two issues. Firstly, individual 375 
approaches to management (despite a focus on multidisciplinary methods) and secondly, 376 
differential access to imaging (68Ga-DOTA-SSA PET/CT is currently not generally available in 377 
the US). There was a full consensus that surgery was potentially curative. Similarly, there was 378 
broad consensus of the utility of 68Ga-DOTA-SSA PET/CT both in establishing a diagnosis and 379 
having a role in staging, predicting response to PRRT and determining prognosis. There are a 380 
number of different national and societal neuroendocrine guidelines that variously evaluate the 381 
usage of biomarkers and imaging (North American – NANETs, National Comprehensive Cancer 382 
Network – NCCN, Canadian NETs and the European Neuroendocrine Tumor Society – ENETs, 383 
[14, 71-75]. Each broadly supports the points defined in this Delphi Consensus but none 384 
specifically addresses the interface between imaging and biomarkers nor the best strategy to 385 
integrate anatomical and functional imaging with circulating molecular information. In particular, 386 
the current consensus meeting evaluated not only the utility of the different strategies (imaging 387 
and biomarkers) but how such modalities could be interfaced to provide a real-time assessment 388 
of the biological evolution of a neuroendocrine neoplasm. It was widely agreed that current 389 
approaches (RECIST) for assessing therapeutic responses were inadequate. In particular, 390 
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clinical knowledge was considered insufficient for early and accurate predictions of progressive 391 
or stable disease. Moreover, it was agreed that a clinically actionable, biologically-relevant 392 
biomarker should be included in treatment response assessments. This is consistent with the 393 
agreement reached in the previous Delphi consensus meeting (2014) that was designed to 394 
specifically address biomarker metrics and clinical utility [61]. 395 
Although biomarkers such as CgA are currently used in conjunction with imaging as 396 
adjuncts for clinical decision making (Figure 3), significant refinements are required [61]. In 397 
particular, implementations of more informative molecular tools such as multianalyte biomarkers 398 
are needed. Dynamic characterization of tumour behavior based upon blood-derived genomic 399 
information is likely to be of considerable clinical utility, especially if used as an adjunct to both 400 
spatial and functional imaging. This is underscored by the lack of utility and clinical effectiveness 401 
of solely secretory biomarkers. For example, CgA does not correlate with imaging, particularly 402 
68Ga-DOTA-SSA and 18F-FDG imaging, while CgA biochemical “responses” to therapy are also 403 
typically non-concordant with imaging [61]. Indeed, a number of national and societal guidelines 404 
adjudge CgA to be “controversial” in clinical decision-making [14, 71]. 405 
Imaging alone, however, also has its limitations. The panel agreed that current 406 
strategies, although useful in diagnosis, were unlikely to be improved in NENs in the near future. 407 
For example, measurements of changes in Hounsfield Units, proposed in the Choi criteria for 408 
measuring GIST treatment responses [15], may not be useful in GEP-NENs. Although suitable 409 
for a rough estimate, SUVmax determined by 
68Ga-SSA-PET/CT, was also not considered to be 410 
ideal, since SSR heterogeneity in individual tumours is a problematic factor for sensitive 411 
assessment of treatment response. Moreover, the differences in intrinsic variabilities in SUVmax 412 
in separate PET/CT scanners at different institutions was a limitation for image-based 413 
assessment and patient follow-up [54]. Changes in tumour SUVmax during PRRT also do not 414 
always correlate to the outcome [25, 76] and in tumours with SUVmax>20-25, SUV does not 415 
linearly correlate with SSR expression [77]. Other imaging biomarkers, such as activated 416 
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glucose metabolisms (18F-FDG-PET) are now being re-evaluated and optimism exists regarding 417 
their future prognostic role in NEN management although prospective validation is required [17]. 418 
While guidelines have, in general, supported serial comparisons between images to evaluate 419 
changes in tumours [14, 71], a RECIST approach has not been recommended in 420 
neuroendocrine tumor disease. This is consistent with the opinions of the experts at this Delphi 421 
consensus who opined that the current configuration of RECIST criteria was sub-optimal for 422 
application to NET disease assessment. Additional parameters that potentially could be 423 
included to improve imaging, however, remained unresolved. The overall consensus was that 424 
adjunct biomarker tools should be developed to provide synergistic information with imaging as 425 
a means to facilitate assessment of therapy. It was agreed that a better understanding of tumour 426 
biology would unquestionably expedite the development of an appropriate therapeutic 427 
biomarker(s). The determination of therapeutic strategy by identification of a biomarker is limited 428 
to the assessment of SSR expression prior to the use of PRRT. The use of current 429 
pharmacological therapy is critically limited by the absence of pre-treatment biomarker 430 
identification and the lack of tools to accurately define efficacy. 431 
Molecular strategies have thus far typically focused on DNA alterations but are clinically 432 
non-informative. Mutations in MEN-1, the predominant sporadic NEN mutation (pancreatic 433 
NENs), are not associated with differences in SSR expression and detection by SRI [78, 79]. 434 
Moreover, the clinical usefulness of alterations in ATRX, DAXX, mTOR signaling [40] and YY1 435 
[80] (all principally identified as sporadic mutations in pancreatic NENs) remain to be proven. 436 
Furthermore, the prognostic and predictive utility of the recently identified IMPK mutation in a 437 
single small bowel carcinoid family [81] remains to be defined. In addition, the clinical 438 
usefulness of chemical-based DNA modifications e.g., methylation, require elucidation. 439 
Alternatives to DNA-based molecular strategies included assessment of CTCs, miRNA, 440 
metabolomics and transcriptome-based approaches. The panel considered miRNA to have 441 
potential utility. Data indicated that tissue-derived microRNAs are detectable in patient serum 442 
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samples and may be altered by somatostatin analogs) [82]. Similarly, metabolomics 443 
investigations were considered of interest since functional and non-functional tumors are readily 444 
separated (R2=0.98) [83]. Further clinical data was necessary to further assess clinical utility. In 445 
respect of CTCs, the consensus was that this parameter remained problematic at the present 446 
time. While there is some literature to support CTCs [84, 85], all represent a single center study 447 
and hence enthusiasm was diminished. Concerns were also raised in regard to technological 448 
aspects of the measurement. Analysis of results demonstrate the clinical sensitivity (number of 449 
patients with detectable CTCs) is low, 33% in the first study and 49% in the second. Such low 450 
numbers may reflect variable EpCAM expression used for tumor cell capture. Irrespective of 451 
technical issues, it remains difficult to reconcile the utility of a test that is based on the absence 452 
or presence of 1 circulating tumor cell. This opinion directly recapitulated that expressed at the 453 
biomarker-focused Delphic consensus meeting (2014) where a separate group of international 454 
experts expressed a similar lack of enthusiasm for the clinical utility of circulating tumor cell 455 
technology [61]. None of these parameters (CTC, miRNA, metabolomics) are currently clinically 456 
recommended in guidelines. Overall, blood-based multianalyte transcript analysis [44, 45], with 457 
a clinical sensitivity >95%, was considered by the group to be more sensitive than standard 458 
biomarkers and of potential clinical utility. This is concordant with the consensus from the 459 
previous Delphi panel (2014) which evaluated the efficacy, metrics and clinical utility of current 460 
NET biomarkers [61]. Its precise application to guiding therapy was considered to require further 461 
evaluation. Current preliminary data [6, 46] were, however, noted to have specifically addressed 462 
clinical utility in sporadic, well-differentiated GEP-NETs. A role in familial NETs (including 463 
germline MEN-1 and VHL mutations) is currently under evaluation. The efficacy of a molecular 464 
tool capable of detecting germline disease evolution over time is of particular clinical relevance 465 
given the low accuracy of current biomarkers and the limitations of imagery (sensitivity and 466 
radiation exposure) as a life-long monitoring tool [86]. The areas of efficacy were identified as 467 
assessment of the effectiveness of curative surgery, assessment of the efficacy of SSA therapy, 468 
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prediction of disease stability/progression and identification of response to PRRT. The signature 469 
was decreased by surgery and values corresponded to the completeness of tumour removal 470 
[49]. In addition, elevated levels following R0 resection predicted subsequent disease 471 
recurrence. In a different study, elevated transcript levels were prognostic of SSA 472 
failure/disease progression [51]. Of note was the observation that alterations in transcript levels 473 
occurred significantly earlier than RECIST- or SRI-based measures of disease progression [51]. 474 
Finally, levels were prognostic for PRRT efficacy and could be used to evaluate therapy, 475 
correlating with image-based assessments [53]. The observation that NEN gene blood levels 476 
correlated with 68Ga-DOTA-SSA PET/CT imaging and could define disease status was 477 
considered worthy of further clinical study [52]. In the latter study, a quotient including specific 478 
genes as well as the SUVmax accurately predicted clinical status. Thus, stable disease could be 479 
differentiated from progression using a time point amalgam of a single image/blood sample. The 480 
group considered that the combination of imaging and circulating blood biomarker offered a 481 
potential for fusing these two functional modalities of treatment assessment into a clinical index 482 
of disease status. This novel consideration had not been previously evaluated at the initial 483 
Delphi analysis (2014) which developed a biomarker-centric analysis of disease management. 484 
The larger and more diverse international cohort of experts that comprised the current Delphi 485 
group was designed to assess the effectiveness and facility of the integration of validated 486 
imaging strategies as a combinatorial clinical assessment tool with biomarkers. 487 
In conclusion, there was consensus among a large (n=33) group of NEN disease experts 488 
from diverse medical and scientific disciplines and countries that current imaging and circulating 489 
biomarkers for NEN disease have substantial limitations for predicting disease activity and for 490 
measuring therapeutic efficacy. In addition, RECIST remains sub-optimal as a metric of disease 491 
status and better tools for assessment as well as improved techniques for imaging require 492 
development. These views broadly recapitulate published guidelines for GEP-NETs [14, 71-75] 493 
while providing a more in depth and detailed evaluation of the strengths and weaknesses of the 494 
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different strategies and how best they might be integrated to provide synergistic information of 495 
clinical utility. It was concluded that a critical requirement was the development of a multianalyte 496 
molecular tool that can better identify disease status and define treatment response. In this 497 
respect, the use of circulating RNA as a biomarker was confirmed to supersede the 498 
effectiveness of standard monoanalyte biomarkers and have potential clinical applicability. This 499 
assessment corroborated the outcome of the previous biomarker-centric Delphi consensus 500 
meeting [61]. Current data suggests added value for the transcript analysis in the monitoring of 501 
diverse therapeutic modalities, particularly in conjunction with other parameters to monitor 502 
disease progression (Figure 4). The NEN experts concluded that combinations of imaging and 503 
blood-based molecular information provided by transcriptome analysis could offer the most 504 
promising future strategy for refining and improving the evaluation of therapy.  505 
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FIGURE LEGENDS 808 
 809 
Figure 1. Clinical utility of imaging overview (Section B).  810 
Imaging for diagnosis (left) was considered effective (71% positive); 68Ga-DOTA-SSA PET/CT 811 
was considered more useful than either 111In-pentetreotide scintigraphy (100%) or 18F-DOPA-812 
PET/CT (89%) for diagnosis of well-differentiated NENs. 18F-DOPA-PET/CT was agreed to 813 
accurately differentiate (88%) low from high grade tumours. Imaging in therapeutic assessment 814 
(right) was overall considered suboptimal (36%). No consensus (grey) could be reached 815 
regarding the utility of either CT/MRI (40%) or PET-CT (46%) in the assessment of therapy. A 816 
combination of CT/MRI and functional imaging were considered useful (84%) There was a 817 
negative assessment of current methodologies including RECIST criteria (82%) and Hounsfield 818 
Units (Choi criteria) (76%). 819 
68Ga = 68Ga-DOTA-SSA PET/CT; 111In = 111In-pentetreotide scintigraphy; 18F =  18F-DOPA-820 
PET/CT; HU = Hounsfield Units 821 
 822 
Figure 2. Biomarker assessment. (Section D).  823 
Current monoanalyte blood biomarkers including CgA, serotonin, and pancreastatin were 824 
overall considered inadequate (80%). The utility for individual strategies was assessed as 825 
negative for CTC’s (70%) and positive, in ascending order, for miRNA (67%), metabolomics 826 
(75%) and circulating mRNA (80%). 827 
 828 
Figure 3. Proposed Strategy for Assessing Therapeutic Efficacy. 829 
An integration of functional imaging and biomarker measurement including circulating tumour 830 
mRNA will provide combinatorial information on a real time basis of disease status. The 831 
combination of individual imaging strategies will quantify tumour location/extent and in addition 832 
delineate somatostatin receptor expression (SRI – typically 68Ga-DOTA-SSA PET/CT) and 833 
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tumour metabolism (18F-FDG-PET/CT). Circulating mRNA will measure tumour biological 834 
activity and identify treatment response. 835 
 836 
Figure 4. Conceptual proposal for the evaluation of therapeutic efficacy. This provides an 837 
integration of functional imaging and tumour molecular biology utilizing circulating multianalyte 838 
assays with algorithm analyses (MAAA)s, mRNA or miRNA. Disease progress can be 839 
delineated using a combination of functional imaging modalities quantifying somatostatin 840 
receptor expression (SSR) by 68Ga-DOTA-SSA PET/CT and tumour metabolism using either 841 
18F-DOPA PET/CT (in well-differentiated tumours) or 18F-FDG (mainly in undifferentiated forms 842 
or to assess tumour aggressiveness). The MAAA e.g., circulating mRNA, provides an accurate 843 
reflection of tumour activity. Overall, the combination of functional imaging (68Ga-SSA and 18F-844 
FDG-PET/CT) and circulating mRNA could, in the future, help to delineate treatment efficacy. 845 
 846 
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